Which Should You Buy: Valeant Pharmaceuticals Intl Inc. or Home Capital Group Inc.?

Home Capital Group Inc. (TSX:HCG) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have seen their stock prices fall this year. Can either company recover?

| More on:
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Stocks that have seen prices decline as a result of scandals and problems present buying opportunities for investors that are not risk averse. The danger in investing in a company that is in turmoil is that the stock could continue to plummet with no end in sight. The easiest example is Sears Canada Inc., which is now in the process of liquidation; months ago, it might have been seen as a bargain opportunity if it could turn things around.

But if is a dangerous word, and just because a stock has declined is not a reason to invest. Instead, it is important, once you find these “bargain” stocks, to look at the company’s financials and assess its long-term prospects. If a company is heavy on debt, sales are declining, and there doesn’t look to be light at the end of the tunnel, it’s best to stay away from the free-falling stock. However, a company ridden by scandals or bad press but has good financials and a promising future might present a good long-term opportunity, as long as you can stomach the fluctuations in the process.

I’ll look at two companies’ stocks that have taken a beating and could present strong long-term upside.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has seen its stock tumble 30% in the past year, and over five years, the stock has declined by over 58%. The company was trading at over $319 a share in September 2015 when news came out about Valeant’s purchase of Addyi, the “female Viagra” pill. The problem with the purchase is, although it was FDA approved, the drug had serious health risks associated with it. Valeant purchased the maker of the high-risk drug for $1 billion, and, as a result, the stock plummeted to $100 a share and soon reached just $34.

Big risks aren’t the only items that have concerned investors. The company is heavily leveraged in debt. At the end of 2015, the company had a debt-to-equity ratio of 5.26 with debt levels reaching over $30 billion. The company was able to bring debt levels down to $29 billion, but a dropping equity resulted in the ratio rising to 9.46 for the end of 2016.

Although the company has expressed a desire to continue paying down its debt, it may be a losing battle, as the company still expects to make large investments into research and development.

Home Capital Group Inc. (TSX:HCG) is a very different case of a company that has been ridden with bad press and scandals in the past several months. The mortgage lender has been involved in fraudulent mortgage applications, and the company’s CEO was fired earlier this year amid accusations of misleading investors.

These types of scandals don’t fade from memory easily, but Berkshire Hathaway Inc. came to the rescue. Berkshire has provided Home Capital with some life support. Home Capital is a bit heavy on debt as well, but with a debt-to-equity ratio of just 1.63 for the latest year, it pales in comparison to the problem Valeant has.

With the problems and individuals associated with fraudulent activities removed from the company, a better balance sheet, and reasonable prospects for a recovery, Home Capital presents a much more attractive opportunity for investors than Valeant.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »